Every patient with advanced pancreatic cancer who visits Dr. Zev Wainberg wants an experimental drug over more chemotherapy. Dr. Wainberg heads the GI Oncology Program at UCLA and is leading trials for a promising new drug called daraxonrasib.
The sad truth is that patients often feel hopeless after conventional treatments start failing. Dr. Wainberg recalls, “Half of my patients receive a placebo, and every one on chemotherapy has passed.”
Recently, excitement around daraxonrasib has soared. In a phase 3 trial with 500 patients, it doubled survival time for advanced pancreatic cancer, moving the average from 6.7 to 13.2 months. These results were showcased at the American Society of Clinical Oncology meeting and also published in the New England Journal of Medicine.
Dr. Rachna Shroff, an oncologist from the University of Arizona Cancer Center, expressed her emotions upon hearing about the results, saying, “It brought tears of joy; it’s a game-changer.” The benefits don’t stop at pancreatic cancer; daraxonrasib also targets a mutation in the KRAS gene, potentially offering new hope to patients with various cancers, including lung and colorectal cancers.
As Dr. Brian Wolpin from Dana-Farber Cancer Institute notes, “Pancreatic cancer might be where we start, but many others will follow.” The drug has gained fast-track FDA approval, allowing it to be given outside clinical trials.
Pancreatic cancer is often diagnosed late, making surgery a challenge. In fact, only 3% of those with metastatic pancreatic cancer survive beyond five years, according to the American Cancer Society. Debby Orcutt, diagnosed with stage 4 cancer, participated in the daraxonrasib trial. She’s reported fantastic results—her liver lesions have vanished and her pancreatic tumor shrank by 80%. “I feel great,” she shares, choosing not to focus on her diagnosis.
Daraxonrasib works by targeting the KRAS mutation, responsible for uncontrolled cell growth in many cancers. For years, scientists struggled to develop a treatment for this mutation. Dr. Wolpin credits recent advancements in chemistry for creating this breakthrough drug.
While daraxonrasib isn’t a cure and tumors can eventually adapt, it marks a significant shift in treatment options. Early studies show that it helps patients even without the KRAS mutation. Meanwhile, Revolution Medicines continues to develop additional related drugs, with more trials on the horizon.
Despite the promise, patients continue to experience some side effects like nausea or skin issues but often find them manageable. Debby commented, “We’re talking life or death here. I can live with a little rash.”
Life moves on for Debby and her husband, Ron. He’s diligent about her medication schedule, reminding her to take pills on an empty stomach. “You just have to keep going,” Debby advises. Each day is a gift, and she’s determined to make the most of her second chance.
In summary, daraxonrasib offers newly found hope for those with pancreatic cancer and potentially other types. With its remarkable results and ongoing research, it paves the way for new treatment strategies that may change lives soon.
For further details, you can check resources from the American Cancer Society and recent clinical findings at credible sources like the New England Journal of Medicine.
Source link
